POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has earned a consensus recommendation of “Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have covered the stock in the last year is $14.33.
Several research firms recently issued reports on PNT. Jefferies Financial Group reissued a “buy” rating and set a $14.00 price target (up from $12.00) on shares of POINT Biopharma Global in a research report on Thursday, July 20th. Raymond James set a $13.00 price target on POINT Biopharma Global and gave the company an “outperform” rating in a research report on Monday, August 28th. Finally, Piper Sandler upped their price target on POINT Biopharma Global from $14.00 to $16.00 in a research report on Wednesday, June 21st.
Institutional Investors Weigh In On POINT Biopharma Global
POINT Biopharma Global Stock Down 0.5 %
PNT opened at $7.35 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.51 and a quick ratio of 10.51. The stock has a market capitalization of $777.41 million, a price-to-earnings ratio of 8.45 and a beta of 0.13. The business has a 50-day moving average of $8.45 and a two-hundred day moving average of $8.49. POINT Biopharma Global has a 12 month low of $5.59 and a 12 month high of $11.13.
POINT Biopharma Global (NASDAQ:PNT – Get Free Report) last announced its earnings results on Monday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.05. The business had revenue of $4.87 million during the quarter, compared to analyst estimates of $8.50 million. On average, research analysts expect that POINT Biopharma Global will post -1 earnings per share for the current year.
POINT Biopharma Global Company Profile
POINT Biopharma Global Inc, a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- Five stocks we like better than POINT Biopharma Global
- How Can Investors Benefit From After-Hours Trading
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Are Growth Stocks and Investing in Them
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What is the NASDAQ Stock Exchange?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.